CASTLE BIOSCIENCES, INC. Asset Acquisition Consideration Transferred Transaction Cost
CASTLE BIOSCIENCES, INC. (CSTL) had Asset Acquisition Consideration Transferred Transaction Cost of $684.00 thousand as of 2021-05-28, per its 10-Q filed 2021-08-09.
Discontinued › Notes
us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost · last filed 2021-08-09
- 2021-05-28: Asset Acquisition Consideration Transferred Transaction Cost $684.00K.
| Period end | Asset Acquisition Consideration Transferred Transaction Cost |
|---|---|
| 2021-05-28 | $684.00K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |